Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.06. | Relay Therapeutics beruft Bicara-CEO in den Vorstand vor Brustkrebsstudie | 17 | Investing.com Deutsch | ||
09.06. | Stifel behält Kaufempfehlung und Kursziel von 48 US-Dollar für Bicara Therapeutics bei | 7 | Investing.com Deutsch | ||
BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
09.06. | Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock | 1 | Investing.com | ||
06.06. | Bicara Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
03.06. | Cantor Fitzgerald maintains overweight rating on Bicara stock | 2 | Investing.com | ||
02.06. | 'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race | 1 | FierceBiotech | ||
02.06. | Stifel bekräftigt Kaufempfehlung für Bicara Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
02.06. | Stifel reiterates Buy rating on Bicara Therapeutics stock | 1 | Investing.com | ||
02.06. | Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock | - | Investing.com | ||
01.06. | ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset | 1 | FierceBiotech | ||
01.06. | Bicara Therapeutics Inc.: Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 | 172 | GlobeNewswire (Europe) | Median DOR of 21.7 months with 80% of responders achieving a deep response (=80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46%... ► Artikel lesen | |
24.05. | Stifel maintains Bicara stock Buy rating, $48 target post-ASCO | 1 | Investing.com | ||
23.05. | Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? | 2 | Benzinga.com | ||
23.05. | Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics | 2 | Investor's Business Daily | ||
23.05. | Bicara falls after early-stage trial data for head and neck cancer therapy | 1 | Seeking Alpha | ||
23.05. | Pre-market Movers: INNEOVA, Snow Lake Resources, Hallador Energy, Lottery.com, Bicara Therapeutics | 625 | AFX News | PLEASANTON (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green INNEOVA Holdings Limited (INEO) is up over 51%... ► Artikel lesen | |
22.05. | Bicara Therapeutics präsentiert Studiendaten zu Kopf- und Halskrebs | 5 | Investing.com Deutsch | ||
22.05. | Bicara Therapeutics-Aktie stürzt nach Veröffentlichung klinischer Studiendaten ab | 2 | Investing.com Deutsch | ||
22.05. | Bicara Therapeutics stock tumbles on clinical trial data | 1 | Investing.com | ||
22.05. | Bicara Therapeutics to present head and neck cancer study data | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SUMMIT THERAPEUTICS | 28,010 | 0,00 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
ARCELLX | 69,97 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 57,09 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 55,74 | 0,00 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,430 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
KYMERA THERAPEUTICS | 46,430 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? | ||
EVOTEC | 6,618 | +4,09 % | Bayer, NetraMark, Evotec: Wie KI-Forschung jetzt Renditen beschleunigt und Ihr Depot optimieren könnte | Die Gesundheitsbranche wird 2025 von KI und Technologien radikal umgekrempelt. Während Pharmariesen unter Kostendruck und regulatorischen Stürmen ächzen revolutionieren Algorithmen die Arzneimittelentwicklung:... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,910 | 0,00 % | Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth | ||
DYNE THERAPEUTICS | 9,380 | 0,00 % | Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr | WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced the pricing of an underwritten public offering of about 24.24 million shares of its common stock at a public offering price of $8.25... ► Artikel lesen | |
ARS PHARMACEUTICALS | 18,000 | 0,00 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
VERVE THERAPEUTICS | 11,110 | 0,00 % | Aktien New York Schluss: Verluste - Sorgen um Krieg in Nahost nehmen zu | NEW YORK (dpa-AFX) - Die sich zuspitzende Lage in Nahost und die Unsicherheit über das weitere Vorgehen der USA haben am Dienstag die US-Börsen belastet. Der New Yorker Leitindex Dow Jones Industrial... ► Artikel lesen | |
NURIX THERAPEUTICS | 11,630 | 0,00 % | Nurix Therapeutics: Günstiger BTK-Player | In der Welt der Biotechnologie zählt die gezielte Zerstörung krankheitsverursachender Proteine zu den innovativsten Ansätzen der modernen Arzneimittelforschung. Nurix Therapeutics, ein Unternehmen mit... ► Artikel lesen | |
QIAGEN | 43,015 | +0,67 % | QIAGEN N.V.: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels | Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications... ► Artikel lesen | |
AMYLYX PHARMACEUTICALS | 8,390 | 0,00 % | TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential | ||
IMMUNOME | 11,450 | 0,00 % | Immunome Inc. - 8-K, Current Report |